---
title: "This Avalo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281762176.md"
description: "Wall Street analysts have initiated coverage on several stocks, including Avalo Therapeutics Inc (NASDAQ:AVTX), which received a Market Outperform rating and a price target of $52 from Citizens analyst Jason Butler. Avalo shares closed at $17.76. Other notable initiations include PayPay Corp (NASDAQ:PAYP) with an Outperform rating and a price target of $26, and Atlas Critical Minerals Corp (NASDAQ:ATCX) with a Buy rating and a price target of $13.75. Analysts have changed their outlooks on various stocks, reflecting a mix of upgrades and downgrades."
datetime: "2026-04-06T12:49:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281762176.md)
  - [en](https://longbridge.com/en/news/281762176.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281762176.md)
---

# This Avalo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   Mizuho analyst Dan Dolev initiated coverage on **PayPay Corp – ADR** (NASDAQ:PAYP) with an Outperform rating and announced a price target of $26. PayPay shares closed at $21.02 on Thursday. See how other analysts view this stock.
-   Citizens analyst Jason Butler initiated coverage on **Avalo Therapeutics Inc** (NASDAQ:AVTX) with a Market Outperform rating and announced a price target of $52. Avalo Therapeutics shares closed at $17.76 on Thursday. See how other analysts view this stock.
-   HC Wainwright & Co. analyst Heiko Ihle initiated coverage on **Atlas Critical Minerals Corp** (NASDAQ:ATCX) with a Buy rating and announced a price target of $13.75. Atlas Critical Minerals shares closed at $5.69 on Thursday. See how other analysts view this stock.
-   Wells Fargo analyst Colin Langan initiated coverage on **Versigent PLC** (NYSE:VGNT) with an Overweight rating and announced a price target of $35. Versigent shares closed at $28.10 on Thursday. See how other analysts view this stock.
-   Benchmark analyst Mark Palmer initiated coverage on **PayPay Corp – ADR** (NASDAQ:PAYP) with a Buy rating and announced a price target of $31. PayPay shares closed at $21.02 on Thursday. See how other analysts view this stock.

Considering buying AVTX stock? Here’s what analysts think:

_Photo via Shutterstock_

### Related Stocks

- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [TMED.US](https://longbridge.com/en/quote/TMED.US.md)
- [AVTX.US](https://longbridge.com/en/quote/AVTX.US.md)
- [BMED.US](https://longbridge.com/en/quote/BMED.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ATCX.US](https://longbridge.com/en/quote/ATCX.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PAYP.US](https://longbridge.com/en/quote/PAYP.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results](https://longbridge.com/en/news/286424446.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)